Radionuclide therapy possibility has also been studied by Amir Iravani et al. in five patients with t-NEPC in which none of them were suitable for PSMA or SSTR-based radionuclide therapy, neither a combination of them, because none of the radiotracers managed to target all sites of the disease, due to the discordant 18F-FDG-avid disease sites and tumour heterogeneity [33]. The gene discussed is FOLH1; the disease is neoplasm.